[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,247,728
  • Shares Outstanding, K 5,699,444
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,384 M
  • EBITDA $ 25,976 M
  • 60-Month Beta 0.35
  • Price/Sales 2.31
  • Price/Cash Flow 5.76
  • Price/Book 1.60

Options Overview Details

View History
  • Implied Volatility 23.53% (+0.58%)
  • Historical Volatility 17.11%
  • IV Percentile 32%
  • IV Rank 33.20%
  • IV High 34.15% on 10/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 2) 0.39 (1.51%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 47,714
  • Volume Avg (30-Day) 131,082
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 2,538,994
  • Open Int (30-Day) 2,533,787
  • Expected Range 25.52 to 26.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.67
  • Number of Estimates 7
  • High Estimate $0.72
  • Low Estimate $0.64
  • Prior Year $0.78
  • Growth Rate Est. (year over year) -14.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.19 +2.72%
on 05/18/26
27.62 -6.32%
on 04/21/26
-1.65 (-5.98%)
since 04/20/26
3-Month
25.19 +2.72%
on 05/18/26
28.75 -9.98%
on 04/02/26
-0.77 (-2.91%)
since 02/20/26
52-Week
22.81 +13.44%
on 05/22/25
28.75 -9.98%
on 04/02/26
+2.35 (+10.01%)
since 05/20/25

Most Recent Stories

More News
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90%...

PFE : 25.68 (+0.08%)
2 Ways to Play the Big Pharma Patent Cliff

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

NVO : 44.75 (+1.06%)
IBB : 166.38 (+1.33%)
ARGX : 800.03 (+0.28%)
PFE : 25.68 (+0.08%)
XBI : 130.09 (+2.60%)
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand therapy, with continued benefit observed in open-label extension study ...

PFE : 25.68 (+0.08%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

BPC.CN : 0.4000 (-4.76%)
PNGAF : 0.2940 (-4.39%)
NVO : 44.75 (+1.06%)
HIMS : 22.62 (+0.80%)
LLY : 1,013.65 (-0.76%)
PFE : 25.68 (+0.08%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance...

BPC.CN : 0.4000 (-4.76%)
PNGAF : 0.2940 (-4.39%)
NVO : 44.75 (+1.06%)
HIMS : 22.62 (+0.80%)
LLY : 1,013.65 (-0.76%)
PFE : 25.68 (+0.08%)
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on...

ARVN : 8.92 (+4.33%)
PFE : 25.68 (+0.08%)
5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call

5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call

PFE : 25.68 (+0.08%)
HHS Explored Potential SSRI Restrictions Ahead of RFK Jr. Push to Reduce Antidepressant Use

U.S. health officials recently explored whether certain selective serotonin reuptake inhibitors, or SSRIs, could face restrictions as Health Secretary Robert F. Kennedy Jr. prepared a broader initiative...

LLY : 1,013.65 (-0.76%)
PFE : 25.68 (+0.08%)
ELV : 397.21 (-1.26%)
Natural Phenomenon or Manufactured Catalyst? The Truth About the 2026 Tick Explosion and Pfizer’s New Vaccine

The spring of 2026 arrived with a vibrant bloom of flowers and an unprecedented, crawling wave of arachnids. Recent social media feeds resemble scenes from a horror movie, a shared experience for millions...

VALN : 5.86 (+1.74%)
PFE : 25.68 (+0.08%)
PFE Q1 Deep Dive: Oncology, Obesity Pipeline, and Legal Milestones Shape Outlook

PFE Q1 Deep Dive: Oncology, Obesity Pipeline, and Legal Milestones Shape Outlook

PFE : 25.68 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.72
2nd Resistance Point 26.34
1st Resistance Point 26.00
Last Price 25.68
1st Support Level 25.28
2nd Support Level 24.90
3rd Support Level 24.56

See More

52-Week High 28.75
Fibonacci 61.8% 26.48
Fibonacci 50% 25.78
Last Price 25.68
Fibonacci 38.2% 25.08
52-Week Low 22.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.